Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02490319
Other study ID # TJCC002
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 2008

Study information

Verified date October 2022
Source Huazhong University of Science and Technology
Contact Xianglin Yuan, MD, PhD
Phone 13667241722
Email yxl@medmail.com.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Radiation pneumonitis is the most common complication and the major dose-limiting toxicity associated with radiotherapy, which can cause poor quality of life or life-threatening symptoms and might hinder the tumor-controlling effects of radiotherapy. Consequently, establishing reliable predictors for the occurrence of RP is of great significance such that the therapeutic effects of RT can be maximized while minimizing its adverse effects. The aim of this study is to figure out the biological prediction models of radiation pneumonitis.


Description:

1. Establish a clinical data base for the lung cancer patients treated with radiotherapy in Tongji Hospital. Data including age, gender, smoking state, KPS, pulmonary function, disease history, histology, stage, surgery, chemotherapy, dosimetric parameters of radiotherapy were collected. Peripheral blood was collected from all patients enrolled. All patients enrolled in this study are examined during and one month after radiotherapy. Then, the patients are followed every three months for the first year and every six months thereafter. At each follow-up visits, all patients are asked to undergo a chest X-ray or CT and clinical information, including symptoms, is collected. RP is graded by two radiation oncologists according to the Common Terminology Criteria for Adverse Events 4.0. 2. Select candidate genes and pathways which may be associated with radiation pneumonitis and identify their tagSNPs by Haploview. 3. Use Kaplan-Meier and Cox model to analyze the association of all the factors collected with radiation pneumonitis. 4. Establish a biological prediction models for radiation pneumonitis based on the statistics analysis


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date
Est. primary completion date July 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Clinical diagnosis of lung cancer by histology 2. Radiation dose at least 45 Gy 3. KPS>60 4. Life expectancy of at least 6 months 5. Voluntarily signed the informed consent Exclusion Criteria: 1. Previous thoracic irradiation 2. Severe cardiopulmonary diseases

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Department of Oncology, Tongji Hospital Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Huazhong University of Science and Technology

Country where clinical trial is conducted

China, 

References & Publications (3)

Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, El Naqa I, Hubbs JL, Lebesque JV, Timmerman RD, Martel MK, Jackson A. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S70-6. doi: 10.1016/j.ijrobp.2009.06.091. Review. — View Citation

Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):5-24. Review. — View Citation

Yuan X, Liao Z, Liu Z, Wang LE, Tucker SL, Mao L, Wang XS, Martel M, Komaki R, Cox JD, Milas L, Wei Q. Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol. 2009 Jul 10;27(20):3370-8. doi: 10.1200/JCO.2008.20.6763. Epub 2009 Apr 20. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary radiation pneumonitis grade >=2 or 3 12 months after radiotherapy
See also
  Status Clinical Trial Phase
Recruiting NCT03803787 - Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients Phase 2
Completed NCT03796364 - Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis Phase 2
Not yet recruiting NCT04632342 - Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients Phase 2
Recruiting NCT05365802 - FAPI PET for Lung Fibrosis Early Phase 1
Completed NCT01754909 - Mitigation of Radiation Pneumonitis and Fibrosis Phase 2
Recruiting NCT05189496 - Hyperbaric Oxygen in the Prevention of Radiation Pneumonitis N/A
Completed NCT01745484 - Role of SPECT in Radiotherapy of Lung Cancer and Toxicity Evaluation N/A
Enrolling by invitation NCT02809456 - Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients Phase 2
Recruiting NCT00155909 - Risk Factors of Radiation Pneumonitis N/A
Recruiting NCT06069115 - Radiotherapy Exposed Lung Injury: Effect on Functioning - Cohort
Completed NCT04863027 - Use of Dual Energy Computed Tomography in Thoracic Radiotherapy Planning.
Not yet recruiting NCT02296281 - Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury Phase 2
Completed NCT03462524 - Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology N/A
Recruiting NCT05448703 - A Study on Predictive Models and Clinical Outcome of Radiation Pneumonitis
Recruiting NCT06079931 - The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia Phase 2
Recruiting NCT04676828 - Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer N/A
Recruiting NCT02735746 - Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis